Biocad, a St. Petersburg-based company, has been granted permission by the Ministry of Health of the Russian Federation to conduct a clinical trial (CT) for a groundbreaking drug aimed at combating type 1 diabetes. Its development has been carried out since 2020 together with specialists from the Russian National Research Medical University named after. N.I. Pirogov, the company’s press service reported.
1 billion rubles invested in development and preclinical research. Preclinical trials completed, evaluating safety and efficacy in Anubis baboons. Clinical trial will study safety, pharmacodynamics, pharmacokinetics, and immunogenicity in human subjects.
According to the company’s explanation, they have developed a drug that uses monoclonal antibodies. This innovative drug has the potential to halt the destruction of pancreatic beta cells in individuals with type 1 diabetes. As a result, it can eliminate or greatly reduce the dependency on insulin therapy for these patients.
